Twist Bioscience Q3 Revenue Jumps 23% to Record High as FY2026 Guidance Raised

The Quick Take

• Twist Bioscience (TWST) Q3 revenue rises 23% to a record high as DNA synthesis demand accelerates
• FY2026 guidance raised as NGS tools and protein solutions drive durable growth beyond pandemic levels
• Biotech tools sector showing sustained demand recovery as pharma R&D spending normalizes

Twist Bioscience Corporation has reported strong fiscal third-quarter 2026 financial results, with revenue jumping approximately 23% year-over-year to a company record, driven by accelerating demand for its DNA synthesis products, next-generation sequencing (NGS) tools, and protein solutions platform. The beat on revenue was accompanied by improved gross margins as manufacturing scale efficiencies continue to offset input cost headwinds.

Management's decision to raise full-year FY2026 guidance reflects confidence that the demand recovery in the biotech tools sector — which has been normalizing since the post-pandemic R&D budget contraction of 2023 — is becoming durable rather than episodic. Twist's DNA synthesis platform, which enables faster and more accurate gene construction for drug development and agricultural applications, is increasingly being adopted as a core research infrastructure tool rather than a discretionary procurement item.

For investors in the biotech tools and genomics space, Twist's results are a positive leading indicator for peer companies including Illumina, Pacific Biosciences, and others that serve the research and clinical genomics market. The Q3 performance suggests that pharma and biotech R&D spending is returning to growth trajectory, creating a revenue expansion cycle for enabling technology providers. Investors will watch Q4 guidance closely to assess whether Twist can sustain or accelerate the 23% growth rate as it scales its next-generation library preparation products.

Synthesized from 1 source.